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One- and two-stage surgical 
revision of infected shoulder 
prostheses following arthroplasty 
surgery: A systematic review and 
meta-analysis
Setor K. Kunutsor  1,2, Vikki Wylde1,2, Andrew D. Beswick2, Michael R. Whitehouse  1,2  
& Ashley W. Blom1,2
Periprosthetic joint infection (PJI) is a catastrophic complication of shoulder arthroplasty. Commonly 
used surgical treatments include one- or two-stage revision, but their effectiveness in controlling 
infection is uncertain. We aimed to compare re-infection (recurrent and new infections) rates; clinical 
measures of function and pain; and noninfection complication rates of one- and two-stage revision 
surgery for shoulder PJI using a systematic review and meta-analysis. We searched MEDLINE, Embase, 
Web of Science, and The Cochrane Library to February 2018. Longitudinal studies conducted in patients 
with shoulder PJI treated exclusively by one- or two-stage revision were eligible. No clinical trials 
were identified. Re-infection rates were meta-analysed using random-effect models after arcsine 
transformation. The re-infection rate (95% CI) in pooled analysis of eight one-stage studies (147 
participants) was 5.3% (1.4–10.6). The corresponding rate for 27 two-stage studies (351 participants) 
was 11.5% (6.0–18.1). Postoperative clinical measures of function and pain were not significantly 
different between the two revision strategies. The pooled noninfection complication rate (95% CI) 
for one-stage and two-stage revision was 12.1% (6.1–19.5) and 18.9% (8.4–31.9) respectively. New 
evidence suggests one-stage revision is at least equally as effective as the two-stage in controlling 
infection, maintaining joint function, and improving complications in shoulder PJI.
For many people with severe gleno-humeral disease, fracture, avascular necrosis or rotator cuff wear, shoulder 
arthroplasty is considered the most effective surgical intervention for alleviating pain and disability. In the UK 
in 2016, about 7000 shoulder arthroplasties were performed1 and across Europe, procedures are more common 
with a six-fold higher rate in Germany2. As with periprosthetic joint infection (PJI) of the hip and knee, deep 
PJI following primary anatomic total shoulder arthroplasty (TSA) is a catastrophic complication which affects 
between 0.4 to 2.9% of patients3–5. The incidence of infection in primary reverse total shoulder arthroplasty (RSA) 
is about six times higher compared with that of primary anatomic TSA6. Treatment of shoulder PJI is a challeng-
ing task with the key aims of infection control, pain relief, and restoration of joint function. There is considerable 
controversy as to the optimal treatment strategy to achieve these aims. Treatment options for PJIs following 
shoulder arthroplasty are similar to those for hip and knee PJI and they include: long-term suppressive antibiotic 
treatment without surgical intervention; debridement, treatment with antibiotics and retention of the prosthesis 
(DAIR); one-stage and two-stage revision; and resection arthroplasty. Choice of treatment strategy is largely 
based on the experiences of treating surgeons and data from hip and knee arthroplasty studies7. Though the 
treatment option depends on the chronicity of infection, organism isolated and its virulence, component stability 
and patient fitness for surgery8, the one- and two-stage revision strategies are preferred as they are associated with 
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successful clearance of infection and good functional outcomes9,10. As with PJIs after hip and knee arthroplasty, 
the two-stage revision strategy is regarded as the standard treatment option for shoulder PJI because it is generally 
consistently associated with good rates of infection control10–12. However, this revision strategy may be associated 
with functional impairment; though some studies have reported improved shoulder function after two-stage 
revision10,12. The one-stage is emerging as a promising alternative option; however, it is not as popular as the 
two-stage strategy. With regards to infection control, the evidence has been inconsistent for one-stage revision. 
Whiles some series have reported good infection control9,13, a high risk of infection recurrence has also been 
reported14. Emerging data suggests that one- and two-stage revision strategies for hip and knee PJI are compara-
ble in terms of infection control15,16. No randomised controlled trial (RCT) has compared the effectiveness of the 
one- and two-stage revision procedures for managing shoulder PJI. However, a number of studies have reviewed 
the existing evidence by comparing results of case series that have reported findings on any of these two revi-
sion strategies and the results have been mostly inconclusive. A qualitative and quantitative review of 30 studies 
that compared infection control and functional outcomes among treatment options for shoulder PJI concluded 
that the one-stage may be as effective as the two-stage revision strategy, though infection control was reported 
to be better with two-stage revision17. However, one-stage revision produced a higher mean Constant-Murley 
(CM) score compared with that of two-stage revision. In another review which was based on six one-stage and 
13 two-stage studies, George and colleagues reported a higher infection eradication rate for one-stage revision 
compared with two-stage revision18. In a recent overview study of existing evidence, the authors concluded that 
two-stage revision is the recommended strategy for PJI of the shoulder, but that a one-stage strategy can be used 
if the infecting organism is identified pre-operatively3.
The current evidence suggests that the optimal treatment strategy for the management of PJI of the shoulder is 
uncertain. There were several features of these previous reviews which limited the generalisability of the findings. 
First, these reviews did not pool the evidence using appropriate meta-analytic methods, which should take into 
account the heterogeneity of the included studies. Second, because the reviews did not pool the evidence using 
standard techniques, potential sources of heterogeneity among the contributing studies were not explored and no 
subgroup analysis was conducted across relevant characteristics. Third, sources of biases such as heterogeneity 
and preferential publication bias were not assessed. Finally, several new individual studies have been published 
recently. In this context, using a systematic review and meta-analysis, we aimed to conduct a detailed and robust 
comparison of the effectiveness of the one- and two-stages revision strategies for shoulder PJI using re-infection 
as a primary outcome and under a range of study-level clinical characteristics. Secondary objectives included (i) 
comparing the effectiveness of the one- and two-stage revision strategies using other clinical outcomes such as 
measures of function, pain, and satisfaction as well as noninfection-related complication rates and (ii) to explore 
for potential sources of heterogeneity between studies and assess publication bias.
Methods
Data sources and search strategy. The review was registered in the PROSPERO prospective register of 
systematic reviews (CRD42017082747) and it was conducted based on a predefined protocol and in accordance 
with PRISMA and MOOSE guidelines19,20 (Appendix 1 and 2). We searched for longitudinal studies (observa-
tional retrospective and prospective cohort studies, case cohort studies, nested case control studies, or RCTs) 
reporting re-infection events and/or other clinical outcomes following one- or two-stage surgical revision of 
infected shoulder prostheses in the following databases: MEDLINE, Embase, Web of Science, and The Cochrane 
library from inception up to 10 February 2018. The computer-based searches combined free and MeSH search 
terms and combination of key words related to the intervention (e.g., “one-stage revision”, “two-stage revision”), 
population (“shoulder arthroplasty”) and PJI (e.g., “prosthetic joint infection”, “deep infection”, “surgical site infec-
tion”). There were no language restrictions. The search was complemented by manually scanning reference lists of 
identified relevant articles and review articles on the topic for publications missed by the original search. Further 
details on the search strategy are presented in Appendix 3.
Eligibility criteria. We included studies that reported recruiting patients with PJI following shoulder arthro-
plasty (anatomic TSA and/or RSA) and who were treated exclusively by a one-stage or two-stage revision strategy, 
and followed post-operatively for re-infection (defined as recurrence of infection by the same organism(s) and/
or re-infection with a new organism(s)) and/or other clinical outcomes such as (i) function [as measured by CM 
score (a commonly used functional score for the shoulder that assesses pain, activities of daily living, range of 
movement, and strength)21, American Shoulder and Elbow Surgeons (ASES) Shoulder Assessment score, Simple 
Shoulder Test (SST), University of California Los Angeles (UCLA) score (function component), Disabilities of 
the Arm Shoulder and Hand score (DASH), Penn Shoulder Score (function component), forward flexion, abduc-
tion, external rotation, and range of motion]; (ii) pain [as measured by pain scores, visual analogue scores (VAS), 
Penn Shoulder Score (pain component), UCLA score (pain component)]; (iii) satisfaction [as measured by Penn 
Shoulder Score (satisfaction component)]; and noninfection-related complications (such as dislocation, fracture, 
loosening, haematoma, postoperative instability, radial nerve entrapment, non-union, and arthrofibrosis).
Data extraction and quality assessment. After the initial screen of titles and abstracts by one reviewer 
(S.K.K.), we acquired potentially relevant articles for detailed full text evaluation. Two independent reviewers 
(S.K.K., V.W.) assessed each article using the inclusion criteria and any disagreements regarding eligibility of an 
article was discussed, and consensus reached with a third author (A.D.B.). The data was independently extracted 
by one reviewer (S.K.K.) using a standardized data collection and quality assessments were also conducted. A 
second reviewer (V.W.) checked these data with that in original articles. We extracted data on year of publication, 
study design, country and geographical location (continent), mean/median baseline age, proportion of males, 
type of index arthroplasty, type of revision surgery, use and type of spacer, revision surgery characteristics, period 
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of follow-up after revision surgery, number of re-infection outcomes and participants, and measures of pain, 
function, and satisfaction. For multiple publications involving the same cohort or series, the study with the most 
comprehensive information was used. We also corresponded with study investigators to provide missing infor-
mation where relevant. We assessed the methodological quality of included studies based on the Methodological 
Index for Non-Randomised Studies (MINORS), a validated instrument which is designed for assessment of the 
quality of non-randomised studies in surgery22 and has been described in previous reports15,16. This tool uses 
eight pre-defined domains namely: a clearly stated aim, inclusion of consecutive patients, prospective collection 
of data, endpoints appropriate to the aim of the study, unbiased assessment of the study endpoint, follow-up 
period appropriate to the aim of the study, loss to follow-up less than 5%, and prospective calculation of the study 
size. For each item, the instrument assigns a score of 0 for “not reported”, 1 for “reported but inadequate”, or 2 for 
“reported and adequate”. These are then summed up into a total score. The global ideal score is 16.
Statistical analysis. The rate of re-infection (estimated from the number of re-infections within follow-up 
period after shoulder revision surgery/total number of participants with PJI or number of shoulder joints with 
PJI) with 95% confidence intervals (CIs) was used as the summary measure across studies. Rates were esti-
mated using the Freeman-Tukey variance stabilising double arcsine transformation23 because of the use of 
binary data with low rates. Details of the method have been reported in previous reports15,16. Summary rates of 
re-infection were pooled using random effects models to account for the effect of between-study heterogeneity24. 
Quantification of the extent of statistical heterogeneity across studies employed standard chi-square tests and the 
I2 statistic25. Potential sources of heterogeneity by study-level and clinically relevant characteristics were explored 
using stratified analysis and meta-regression26. Publication bias was assessed using Egger’s regression symmetry 
test27. Noninfection-related complication rates (estimated from the number of complications within follow-up 
period after shoulder revision surgery/total number of participants with PJI or number of shoulder joints with 
PJI) with 95% CIs were also estimated. Other clinical measures of function and pain were compared between the 
two revision strategies using descriptive statistics (Wilcoxon rank-sum tests). We employed Stata version 14 (Stata 
Corp, College Station, Texas, USA) for all statistical analyses.
Results
Study identification and selection. The computer search and manual screening of reference lists of rel-
evant studies identified 708 potentially relevant citations. After exclusions based on titles and abstracts, 55 arti-
cles remained for detailed evaluation. The remaining 30 articles were pertinent to the review question and were 
included in the pooled analysis (Fig. 1; Tables 1 and 2; Appendix 4). Overall, there were 35 unique study popu-
lations (comprising of 498 participants or shoulders revised for PJI and 69 re-infections) eligible for the review.
Study characteristics and study quality. Table 1 summarises baseline characteristics of one- and 
two-stage revision studies included in the review and Table 2 provides baseline characteristics and quality 
assessment scores of the individual studies. There were no significant differences in baseline study level surgery 
and clinical characteristics between the two revision strategies. All included studies were based on retrospec-
tive analyses of observational cohort data. No clinical trials comparing both revision strategies were identified. 
Cutibacterium acnes (C. acnes) was the most commonly causative organism for PJI of the shoulder in the majority 
of eligible studies. Studies were carried out in Europe (Austria, Belgium, France, Germany, and Switzerland), 
North America (United States of America), and Asia (South Korea). The methodological quality of included 
studies ranged from 8–12.
One-stage revision and re-infection. Eight studies comprising of 147 participants evaluated the 
one-stage revision strategy and recorded 12 re-infections on follow-up (Tables 1 and 2). The pooled random 
effects re-infection rate (95% CI) was 5.3% (1.4–10.6; p < 0.001) (Fig. 2). The 95% prediction interval for the 
pooled re-infection rate was 0.8 to 12.2%, suggesting that the true re-infection rate for any single new study will 
usually fall within this range. There was no evidence of heterogeneity between contributing studies (I2 = 0%, 
95% CI: 0–68%; p = 0.40). There was no statistically significant evidence of publication bias using the Egger test 
(p = 0.66).
Two-stage revision and re-infection. Twenty-seven studies comprising of 351 participants with PJI of the 
shoulder reported 57 re-infections following two-stage surgical revision (Tables 1 and 2). The pooled re-infection 
rate (95% CI) was 11.5% (6.0–18.1; p < 0.001) with a 95% prediction interval of 0.0 to 40.3% (Fig. 3). There was 
moderate heterogeneity between contributing studies (I2 = 50%, 22–68%; p < 0.01), which was not explained by 
any of the study-level characteristics assessed in subgroup analyses (Appendix 5). Heterogeneity was substan-
tially reduced (I2 = 41%, 0–73%; p = 0.10), when we restricted the analysis to studies of the highest quality (≥11). 
Among the higher quality studies, the pooled re-infection rate (95% CI) was 10.4 (4.0–18.5; P < 0.001), which was 
similar to the main finding. There was no evidence of publication bias (Egger’s p = 0.71).
In a subgroup analysis that compared re-infection rates between the two revision strategies, no significant 
difference was observed (p-value for meta-regression = 0.41).
Other post-operative clinical outcomes. Fifteen studies (4 one-stage and 11 two-stage studies) reported 
on complications following revision surgery and these included dislocations; humeral or clavicular frac-
ture; humeral or glenoid loosening; haematoma; postoperative instability; radial nerve entrapment and palsy; 
non-union; glenoid baseplate failure; glenosphere dissociation; and arthrofibrosis (Table 2). The pooled non-
infection complication rates (95% CIs) for one-stage and two-stage revision were 12.1% (6.1–19.5; p < 0.001) 
and 18.9% (8.4–31.9; p < 0.001) respectively. In meta-regression analysis, no significant difference was observed 
(p-value for meta-regression = 0.62).
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There were no significant differences in measures of function and pain between both revision strategies 
(Table 3). However, the scores for CM, forward flexion and abduction were better in the one-stage revision group 
compared with two-stage stage revision group; whereas scores for ASES, SST, external rotation, internal rotation, 
and Penn Shoulder were better in the two-stage revision group. Data on measures of satisfaction was very limited 
and could not be compared.
Discussion
Key findings. We have compared the effectiveness of one- and two-stage revision strategies for PJI following 
shoulder arthroplasty using a systematic review and meta-analytic approach. Our primary outcome was re-infec-
tion (recurrent and new infections) with clinical measures of function and pain as well as noninfection complica-
tion rates employed as secondary outcomes. Pooled analysis showed that one-stage revision was associated with a 
markedly lower re-infection rate (5.3%) compared with the two-stage strategy (11.5%), though the difference was 
not statistically significant. Re-infection rates were generally similar across several study level clinically relevant 
characteristics for two-stage revision. The noninfection complication rate was also lower for one-stage revision 
compared with two-stage revision, though not significantly different. Though there were no significant differences 
in measures of function and pain between the two revision strategies, scores for CM, forward flexion, and abduc-
tion were better in one-stage revision patients; whereas scores for ASES, SST, external rotation, internal rotation, 
and Penn Shoulder were better in two-stage revision patients. However, given the limited data for these clinical 
outcomes, the findings should be interpreted with caution.
Comparison with previous work. In this comprehensive quantitative review, we report several relevant find-
ings that have not been previously reported. Some of our findings are also consistent with that of previous reviews 
on the topic. Consistent with our results, George and colleagues in their review of 20 studies reported that one-stage 
revision was associated with better infection control compared with two-stage revision and the difference was not 
significant18. Functional outcomes as measured by CM score was also better for the one-stage revision. In a system-
atic review including 15 studies, Marcheggiani and colleagues reported significantly better infection control rates for 
one-stage revision compared to two-stage revision, with no difference between CM scores28. Nelson and colleagues 
reported higher infection control for two-stage revision; however, in their systematic review including 30 studies, 
the difference between the two strategies was not significant17. The CM score for one-stage revision was also better 
but not significantly different. In our study, we employed a robust meta-analytical approach which took into account 
appropriate weighting of studies, whereas previous reviews simply summed the number of patients and number of 
Figure 1. PRISMA flow diagram.
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infections, an approach which gives misleading results29. In addition to reporting data on noninfection complica-
tion rates and other measures of function as well as pain, we were careful not to include studies with overlapping 
participants; an approach that was ignored by the previous reviews. For example, the study of Klatte et al.30, included 
participants that had been included in the two studies of Ince et al.13,31. We also only included studies of patients with 
PJI following a shoulder arthroplasty as the index procedure and not other procedures such as rotator cuff surgery 
and internal fixation; as inclusion of these could have biased our results. In the absence of clinical trial data, our 
results provide up-to-date reliable evidence on the comparative effectiveness of the two revision strategies, as they 
are based on a larger number of studies and outcomes and employed a meta-analytic approach taking into account 
the heterogeneity between contributing studies.
Implications of our findings. Overall, findings from our study suggest that the one-stage revision strategy for 
the management of PJI of the shoulder is at least equally as effective as the two-stage in terms of infection control 
and maintenance of joint function. Indeed, the principal aim of treatment is to eradicate and prevent recurrence of 
infection as well as optimise joint function32. Noninfection complications were also lower for one-stage revision. 
There are no clear management guidelines or consensus as to which revision strategy to use for PJI of the shoul-
der. Considerable research into the treatment of PJI has been carried out in patients with lower limb arthroplasty 
and this body of evidence has provided insight for treatment of shoulder infection7. However, infections in shoul-
der arthroplasty are characterised by different infective organisms, signs and symptoms, laboratory data, and also 
run a different clinical course33. The treatment of PJIs in the shoulder joint is indeed a challenging task for both 
the surgeon and the healthcare system. George et al. report that unlike PJI after hip and knee arthroplasty, the 
two-stage revision is not considered the “gold standard” for the management of PJI following shoulder arthroplasty, 
as there are other treatment options which report favourable outcomes18. However, the two-stage revision is gen-
erally considered as the standard treatment. The two-stage procedure which is considered the treatment of choice 
in patients who are medically stable9,30,34,35 and recommended when the infective microorganism is unknown3, 
One-stage revision Two-stage revision P-value
Eligible studies
Total number of studies included 8 27
Participants
Total number of participants 147 351
Total number of re-infections 12 57
Median (IQR) age (years) 66.3 (64.0–67.3) 63.0 (62.0–65.0) 0.31
Median (IQR) males (%) 68.3 (57.2–79.2) 62.5 (41.7–73.5) 0.32
Location, number of studies (number of participants)
Europe 6 (85) 11 (131)
North America 2 (62) 15 (208)
Asia 0 (0) 1 (12)
Study and surgery characteristics
Median (IQR) time from index surgery to infection diagnosis (months) 4.0 (4.0–4.0) 25.2 (8.1–40.2) 0.48
Median (IQR) time from index surgery to revision surgery (months) 15.2 (15.2–15.2) 24.0 (8.0–40.0) >0.99
Median (IQR) from infection diagnosis to revision surgery (months) 28.0 (28.0–28.0) 9.5 (2.5–14.0) 0.18
Median (IQR) interval between stages (months) — 4.0 (3.0–6.6)
Median (IQR) follow-up (years) 3.0 (3.0–3.8) 3.9 (3.0–4.5) 0.36
Methodological quality (IQR) 10 (10–11) 10 (10–11) 0.77
Baseline clinical characteristics
Median (IQR) Constant-Murley score 31.5 (27.5–37.4) 29.0 (21.0–34.5) 0.47
Median (IQR) ASES total score 33.6 (33.6–33.6) 32.0 (31.7–32.3) 0.22
Median (IQR) ASES function score 10.6 (10.6–10.6) 11.2 (11.2–11.2) 0.32
Median (IQR) SST score 1.8 (1.8–1.8) 1.8 (1.8–1.8) NE
Median (IQR) Forward flexion 57.0 (57.0–57.0) 58.0 (45.0–60.0) 0.77
Median (IQR) External rotation 23.0 (23.0–23.0) 14.0 (13.0–14.0) 0.37
Median (IQR) Internal rotation 3.0 (3.0–3.0) 2.0 (2.0–2.0) 0.32
Median (IQR) Abduction 46.0 (46.0–46.0) 51.0 (42.0–60.0) >0.99
Median (IQR) Penn shoulder total score — 24.9 (24.9–24.9) NE
Median (IQR) ASES pain score 24.2 (24.2–24.2) 20.5 (20.5–20.5) 0.32
Median (IQR) Pain score* — 4.2 (4.2–4.4) —
Median (IQR) VAS score — 7.08 (7.08–7.08) —
Table 1. Summary characteristics of included studies. ASES, American Shoulder and Elbow Surgeons; IQR, 
interquartile range; NE, not estimated; SST, Simple Shoulder Test; VAS, visual analog scale. *None of the one-
stage revision studies reported scores for these clinical characteristics.
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has been commonly associated with successful eradication of infection in several case series34,36,37. However, this 
procedure frequently results in significant functional impairment38, given the requirement for two major surgical 
procedures. It is also costly for the healthcare system. The hospital cost of two-stage revision for the treatment of an 
infected shoulder arthroplasty is about two times higher than the cost of a primary shoulder arthroplasty39. The use 
of the one-stage revision strategy for managing PJI of the shoulder is becoming increasingly popular, though it has 
not gained the same level of momentum as with the treatment of PJI following hip arthroplasty. The main advantage 
Lead Author, 
Publication Date 
(Reference No.) Location
Year of 
study
Mean/
median 
age 
(years)
% 
male
Mean/
median 
interval 
between 
stages 
(months)
Type of index 
arthroplasty
Common 
infecting 
organism (s)
Follow 
up 
Mean/
median 
(years)
No. of re-
infections
No. of 
noninfection 
complications
No. of 
participants 
or shoulders
Quality 
score
One-stage
Coste, 2004 France 1991–1999 NR NR NA NR
S. 
epidermidis, 
S. albus, C. 
acnes
2.7* 0 NR 3 10
Beekman, 2010 Belgium 2005–2007 62.0 81.8 NA RSA C. acnes 2.0 1 3 11 11
Grosso, 2012 USA 2001–2009 66.5 76.5 NA Mix C. acnes 3.0 1 1 17 11
Amaravathi, 2012 France 1993–2008 NR NR NA NR S. epidermidis 2.5* 4 NR 12 10
Klatte, 2013 Germany 1990–2010 66.0 54.3 NA Mix S. epidermidis 4.7 2 5 35 8
Middernacht, 2014 Belgium 2004–2009 NR NR NA RSA C. acnes 3.4* 2 NR 19 12
Jacquot, 2015 France 1996–2011 NR NR NA RSA C. acnes 3.0* 0 NR 5 10
Stone, 2017 USA 2004–2012 68.0 60.0 NA NR C. acnes 3.8* 2 5 45 10
Two-stage
Sperling, 2001 USA 1972–1994 NR NR 6.6 NR
Pseudomonas 
diminuta, 
CNSA, SA
4.8 0 NR 3 10
Seitz, 2002 USA NR 62.0* 62.5* NR NR S. aureus* 4.8* 0 NR 5 9
Jerosch, 2003 Germany NR 71.0* NR NR NR S. aureus 0.5–2.5* 0 NR 10 9
Coste, 2004 France 1991–1999 NR NR NR NR S. epidermidis 2.7* 4 NR 10 10
Mileti, 2004 USA 1975–2000 58.0 25.0 NR Mix S. epidermidis 7.4 0 NR 4 10
Dines, 2006 USA NR NR NR NR NR NR 6.3* 0 NR 3 10
Strickland, 2008 USA 1995–2004 62.0 58.8 2.5 NR C. acnes or CNSA 2.9 7 14 19 10
Kelly, 2009 USA 2005–2007 NR NR NR Mix C. acnes 1.8* 2 NR 8 9
Dodson, 2010 USA 2002–2006 NR NR NR NR C. acnes 4.0* 2 NR 5 10
Hattrup, 2010 USA 1997–2005 NR NR 6.6 NR CNSA 4.1 3 NR 20 9
Stine, 2010 USA 2003–2007 NR NR NR NR NR 2.3 0 3 12 10
Jawa, 2011 USA 2000–2006 63.0 71.4 8.9 Mix C. acnes 2.3 5 4 28 11
Sabesan, 2011 USA 2001–2009 67.6 58.8 4.0 Mix CNSA 3.9 1 5 17 11
Weber, 2011 Germany 1998–2008 62.5 50.0 NR NR NR 4.0* 0 NR 4 11
Amaravathi, 2012 France 1993–2008 NR NR NR NR C. acnes 2.5* 6 NR 12 10
Romano, 2012
Multiple 
countries in 
Europe
1999–2009 NR NR NR Mix MRSA 3.4* 0 NR 17 11
Achermann, 2013 Switzerland 1998–2010 61.6 16.6 3.0 Anatomic and RSA S. species 3.8 1 NR 7 10
Ghijselings, 2013 Belgium 2001–2012 65.0 33.3 3.2 Mix NR 4.7 0 1 3 10
Ortmaier, 2014 Austria 1998–2010 NR 75.0 ≥3.0 RSA NR >2.0* 3 2 12 11
Middernacht, 2014 Belgium 2004–2009 NR NR NR RSA C. acnes* 3.4* 1 NR 4 12
Jacquot, 2015 France 1996–2011 NR NR NR RSA C. acnes 3.0* 5 NR 14 9
Zhang, 2015 USA 2005–2012 69.0* 83.3* NR Mix C. acnes 2.0* 0 NR 11 10
Assenmacher, 2017 USA 1980–2010 65.0 73.5 2.5 Mix C. acnes 4.1 6 2 35 12
Buchalter, 2017 USA 2000–2014 63.0 74.0 4.9 Mix C. acnes 5.3 5 3 19 11
Lee, 2017 Korea 2009–2014 69.5 41.7 NR Mix MRSA 3.4 0 2 12 10
Stone, 2017 USA 2004–2012 65.0 68.0 NR NR C. acnes 3.8* 4 2 19 10
Grubhofer, 2018 Switzerland 2000–2013 62.0 63.2 7.0 Mix CNSA 4.3 2 2 38 11
Table 2. Characteristics of studies included in review. C, Cutibacterium; CNSA, Coagulase negative 
Staphylococcus aureus; MRSA, Methicillin resistant Staphylococcus aureus; NA, not applicable; NR, not 
reported; RSA, reverse total shoulder arthroplasty; S, Staphylococcus; *for the entire sample; Mix, mixture of 
hemiarthroplasty, anatomic total shoulder arthroplasty, and reverse total shoulder arthroplasty.
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of this procedure is that only one surgery is required, therefore it is associated with shorter hospital stay and gen-
erally shorter antibiotic duration13,30,32. The one-stage procedure is also associated with less tissue destruction and 
dissection, less patient anxiety, has the potential for better functional outcomes, and is associated with cost-benefits 
compared with the two-stage strategy4,13,32,40. Given the limited opportunities for further antibiotic therapy, the 
one-stage revision has commonly been adopted in select cases where the causative organisms have been identified 
pre-operatively41. Functional outcomes for one-stage revision have also been suggested to be dependent on the 
integrity of the rotator cuff muscles and type of prosthesis used41. Given the abundance of literature showing C. acnes 
Figure 2. Rates of re-infection in patients treated by one-stage revision. The summary estimates presented were 
calculated using random effects models; CI, confidence interval (bars).
Figure 3. Rate of re-infection in patients treated by two-stage revision. The summary estimates presented were 
calculated using random effects models; CI, confidence interval (bars).
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as the common organism responsible for PJIs of the shoulder which is consistent with our findings, the potential 
to use the one-stage in a less selective manner is a possibility. Indeed, C. acnes is a gram-positive anaerobic bacillus 
which can be found in high concentrations in the acromion42 and can take up to four weeks to manifest as positive 
cultures43. PJI of the shoulder is associated with significant burden to the patient clinically and socioeconomically5 
and also a challenge to the surgeon7,44. It also presents a huge financial burden to health systems5,39 and therefore a 
greater need to optimise resources. Indeed, previous reports suggest that shoulder PJIs have higher morbidity and 
costs compared with PJIs of other joints45,46. The current findings provide supportive evidence that the one-stage 
may be a potentially more attractive option for managing PJIs of the shoulders.
Strengths and limitations. In addition to the several strengths enumerated above, our review employed a 
comprehensive search of several databases which yielded a large number of eligible studies compared to previous 
reviews on the topic. This ensured a more reliable comparison of the effectiveness of the two revision strategies 
in more detail than ever before. A detailed assessment of the methodological quality of the included studies was 
conducted using a well-established validated instrument. We adopted robust meta-analytic approaches which 
took into account the low event rates of the majority of the studies and heterogeneity between contributing stud-
ies. Other approaches included reporting of prediction intervals, comparison of re-infection rates among several 
clinically relevant characteristics, quantification of heterogeneity between studies and exploration of potential 
sources of bias. Our analyses showed no statistical evidence of publication bias and substantial heterogeneity 
between contributing studies for both revision strategies.
Several limitations deserve consideration. There was a comparatively smaller number of one-stage studies and 
limited data on the secondary clinical outcomes, which precluded the ability to robustly compare the two revision 
strategies head-to-head. The sparse data also precluded detailed subgroup analyses by relevant characteristics 
which could have influenced the outcomes such as sex, indication for primary procedure, co-morbidities, type of 
infecting organism, type of implant, and antibiotic duration. We contacted several authors to provide additional 
data but received only one response. Given the nature of data reported by contributing studies, we were unable 
to distinguish between cases of anatomic TSA versus RSA, revision versus primary shoulder arthroplasty, as well 
as recurrent versus new infections. Given the limitations of aggregate published data, these findings should be 
interpreted with caution. However, the current findings are both timely and relevant and highlight the one-stage 
revision strategy as an equally or more effective option for treating PJI of the shoulder. In the absence of a care-
fully designed RCT powered for re-infection outcomes to robustly compare the effectiveness of the two revision 
strategies, access to individual level data from published studies may help to confirm the present findings. Our 
group has recently successfully employed this approach to compare the effectiveness of the one- and two-stage 
revision strategies for the management of PJI of the hip47. Finally, there is a potential that data from national joint 
registries may be extremely useful in answering these questions, given their large-scale nature and cohort designs. 
However, no studies using registry data were eligible for the current review.
In conclusion, new evidence suggests the one-stage revision strategy is at least equally as effective as the 
two-stage revision strategy in controlling infection and improving function and pain as well noninfection com-
plication rates in PJI of the shoulder following joint arthroplasty.
Data Availability Statement
All data analysed during this study are available on reasonable request to the corresponding author.
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